ScreenerHero

KROS Keros Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · kerostx.com
11.21USD+1.82%Mkt Cap: 222.26M $P/E: —

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-be…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap222.26M USD
Enterprise Value-23.58M USD
Revenue (TTM)15.01M USD
Gross Profit-58.34M USD
Net Income (TTM)87.01M USD
Revenue/Share0.56 USD
Last Price11.21 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees92
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.66
PEG—
EV/EBITDA0.24
EV/Revenue-1.57
P/S14.54
P/B0.83
EPS (TTM)-3.22
EPS (Forward)-6.62
52W Range
9.69012% of range22.55
52W High22.55 USD
52W Low9.690 USD
Profitability
Gross Margin0.00%
Oper. Margin-655.84%
EBITDA Margin0.00%
Profit Margin35.65%
ROE28.70%
ROA25.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF107.50M USD
CapEx (TTM)1.55M USD
FCF Margin-180.99%
FCF Yield-12.23%
Net Debt-241.88M USD
Net Debt/EBITDA2.50
Balance Sheet
Debt/Equity0.06
Current Ratio21.96
Quick Ratio21.47
Book Value/Sh13.23 USD
Cash/Share12.99 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)19.83 USD
Upside (mean)+76.9%
Target Range16.00 USD – 25.00 USD
16.00+76.9% to mean25.00
# Analysts6
Ownership
Shares Out.19.83M
Float17.77M
Insiders3.96%
Institutions95.23%
Short Interest
Short Ratio7.7d
Short % Float7.79%
Short % Out.6.77%
Shares Short1.34M
Short (prev mo.)1.15M
Technical
SMA 5010.96 (+2.2%)
SMA 20012.87 (-12.9%)
Beta1.12
S&P 52W Chg16.45%
Avg Vol (30d)178.38K
Avg Vol (10d)181.00K
Technical Indicators
RSI (14)49.9
MACD0.0791
MACD Signal0.1311
MACD Hist.-0.0520
BB Upper11.73 USD
BB Middle11.33 USD
BB Lower10.93 USD
BB Width7.08%
ATR (14)0.4815 USD
Vol Ratio (20d)1.08x